Welcome to the first 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. As in past editions, each monthly installment will provide articles and news items highlighting the latest in research and treatment paradigms for MPNs. A special upcoming edition will feature a case-based video roundtable discussion during which three experts in the field and I will highlight the current state of MPN treatment and management.
In this January 2018 edition, we explore the latest data coming out of the 2017 American Society of Hematology Annual Meeting, including a Revised DIPSS-Plus scoring system, updated findings from the RESPONSE trial, and cutting-edge research on targeted therapies for MPNs. We also take a look at a recent study showing increased risk for thrombotic events among patients with MPNs, and we learn how the JAK2 inhibitor fedratinib is making a comeback.
I also encourage you to check out last year’s video roundtable panel discussion, “Perspectives on the Collaborative Management of Myeloproliferative Neoplasms” as a refresher.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at firstname.lastname@example.org at any time.
I hope you find this to be a useful and enduring resource in your practice!
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus